Are you looking for Concord Biotech IPO GMP? Your search ends here, as we offer comprehensive details about the grey market premium on this page.
An IPO is a significant milestone for a company, marking its shift from a privately held entity to a publicly-traded one. It serves as a means to raise capital and expand operations.
Investors participating in IPOs have the opportunity to become shareholders of the company and potentially profit from its future growth. Let’s begin without any further delay and learn about the GMP of Rekha Jhunjhunwala-backed Concord Biotech.
About Concord Biotech
Concord Biotech Limited is a research and development (R&D) oriented biopharmaceutical company that specializes in the production of Active Pharmaceutical Ingredients (API) using fermentation and semi-synthetic processes, as well as finished formulations.
Established in 2000, the company has a strong global presence, supplying its products to 70 countries, including the USA, Europe, Japan, Latin America, Africa, and Asia. Mr. Sudhir Vaid holds the position of Chairman and Managing Director (MD) at the company.
Trending Now: SBFC Finance IPO GMP Updates
Concord Biotech IPO Important Dates
Concord Biotech IPO Details
Concord Biotech Fundamental Analysis
Concord Biotech has recently launched an IPO, which is entirely an OFS (Offer for Sale). This means that existing investors are selling their stake through this offering. The company has shown good revenue growth over time. As of March 2021, its revenue was Rs. 630.75 Crore, and the profit after tax (PAT) stood at Rs. 234.89 Crore.
Moving to March 2023, Concord Biotech’s revenue reached Rs. 888.48 Crore, and the PAT amounted to Rs. 240.08 Crore. While the profit growth is not particularly impressive, the company does possess the potential to boost its profits further. According to the latest data, the company’s borrowings amount to Rs. 31.24 Crore, and it currently maintains a Return on Net Worth (RONW) of 20%. Here is a summary of Concord Biotech’s financial numbers.
Concord Biotech IPO GMP Today
Investors are strongly advised to conduct thorough analysis before investing in an IPO. Relying solely on the Grey Market Premium (GMP) is not advisable, as the GMP tends to fluctuate rapidly, and there is no guarantee that the stock will actually deliver the expected returns indicated by the GMP. However, in many cases, a positive GMP does provide a good indication of potential listing gains.